Zeomedix is a development stage company devoted to creating novel therapies for infected and/or difficult to heal wounds based on its nitric oxide (NO) releasing technology. It is well-known in the scientific literature that nitric oxide acts as broad-spectrum antimicrobial agent and enhances the wound healing process through angiogenesis. However, delivering nitric oxide to a wound site in a patient-friendly manner has proven challenging because the molecule is a gas.
Zeomedix technology obviates the problems of nitric oxide storage and controlled delivery for wound care treatment. The Company’s long-term mission is to develop and commercialize a portfolio of innovative products to treat a variety of skin, soft tissue, and wound infections.